Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Was hoping for a bit more excitement. Hopefully it ticks up a bit more before close and pops huge tomorrow. BOL
2.61 M
Total volume
1.56 M
CSE vol
1.05 M
ATS vol
Imagin management will host a conference call at 5:00 p.m. ET to review the financial results
and discuss business developments in the period
I did not say it was FDA. It is a trial to collect data to present to the FDA. Which was updated on Feb 15 and the very next business day the company announced a conference call. Im liking our chances here. Lets see where its at about this time Thursday morning.
https://clinicaltrials.gov/ct2/show/NCT03058705?cond=Bladder+Cancer&cntry=US&state=US%3ANY&city=Rochester&rank=2
Looks like the trial was updated a week ago. Hopefully that's Dr Messing putting his stamp on it and he's ready to publish results. Pretty nice coincidence with the update on the trial and a conference call coming.
CONFERENCE CALL FEB 27 2019 5 PM
Everyone get your questions ready.
https://webfiles.thecse.com/Press_Release_2.19.2019_Imagin_Q1_Investor_Call_Notice_PR_final.pdf?30Ei38QdN8Ov_p16PrDfBv3IT4U6rQTC
NOBLECON15 JIM HUTCHENS PRESENTATION
http://noble.mediasite.com/Mediasite/Play/14eeb5b989c64caea92d4f2b2217592a1d
In the URMC Research Study, fluorescence was successfully demonstrated in 15 minutes,
confirming that the i/Blue Imaging System will potentially allow physicians to “see” bladder
cancer significantly faster than the full hour or more required by currently available imaging
technology.
https://webfiles.thecse.com/Press_Release_-_IME_-_Research_Study_Progress_-_Final_7.17.18.pdf?OdIvva8Gii2BISJHdlRDMTXBcevRQNGp
Keep those shares in a safe place. They are going to be worth a fortune and sooner than you'd think.
Presenting at Noblecon 2019
https://www.noblelinx.com/presenters.php
Stockhouse is toxic. They will let everything fly over there.
Replying to the part of your post referring to having to do another pp. They have .38 warrants out there that equals just over 3.9 million. They will get those cashed 1st before any more public financing is done. Use that as a bench mark of where the sp is going. But keep in ming that those warrants are not expiring until april 2020.
If in fact they do raise more $$ it wont be from a pp, it most likely will come from an investment firm, and we wont be able to get in on it.
Roughly a year ago the sp was at .42. Its not impossible to see that again this year.
Dr Messing had to wait 6 months before he can post results from the trial. Hoping he posts them right away. End of Jan is the earliest.
Aint nothin to see here yet. Need time. Its gonna happen. Patience.
Monthly repprt for October is not due until Nov 7th. So if they want to take their time they can.
Im curious to see if they cashed that million over the month. They had about 11 million warrants @.10
Good for you man. Whenever i throw an email like that at companies, I'm always ignored. But I'm not insulted over it. Usually I'm pissed off and asking too much.
I suspect they will not reply to that, but good for you for speaking your mind.
I think we will be hearing from the FDA soon about where they will class our device. Hopefully that with Optel news and news on the next set of trials will spike this up.
The company has a lot of money coming if they can get the .38 warrants cashed (which im positive they will) Its just a matterer of time and patience for us.
LOL welcome to the CSE where all companies used to be mining companies. Do some homework for once
Cannabix Technologies used to be West Point Resources.. went public @ 0.05
Have a look at them now. And they don't even have a patent IME has at least 3. And a positive clinical trial. Buy and wait.
Names of Dr's or you are lying.
Even with 1 more round of serious financing, this could and should be a $2 buyout.
In the meantime we could and should hit $1 on speculation alone.
All my opinion but i know i am not alone.
Imagin Medical recognizes bladder cancer with computer-aided optics
Bladder cancer is the fourth most common cancer in men, and it is also the one with the highest relapse rate. For those affected, but also for the treating physicians, the fear of the recurrence of the disease is often very stressful. The problem is that the boundaries of the tumor are often difficult to detect with existing imaging techniques. A relapse can only be really avoided if the damaged tissue is removed without residue. The American Urological Society says it clearly: "Incomplete [tumor] removal is likely to be a significant factor in high bladder cancer recurrence." For decades, urologists have relied on the combination of contrast agents and simple optical devices with white light to diagnose and treat bladder cancer. This method has error rates of up to 67 percent. Therefore, with these agents, it is often difficult to accurately detect the edges of the tumor. Exactly for this problem wants the US-based medical technology company I Magin Medical (CSE: IME; FRA: DPD2) offer with its new computerized optics a new solution. In the summer of this year, the so-called i / Blue system was successfully tested in a ten-fold test at the University of Rochester Medical Center
In a study, a fourfold improvement in the speed and accuracy of tumor identification was demonstrated. In parallel experiments, the company announced the successful completion of the critical "proof of concept" phase for its optical modules. The company has completed development of an alpha prototype for its i / Blue imaging technology. In other words, there is a working product! The pure research & development phase is complete. With this successful milestone on the way to commercializing a finished product, Imagin has now officially launched the i / Blue imaging system application process with the FDA.
New strong man on board with access to the industry
Leading the approval process will be veteran entrepreneur Chris Bleck, who has just been appointed to Imagin's board of directors. Bleck has over 30 years of experience in the international healthcare industry. He was responsible for numerous clinical development programs, product launches and stock market rounds, as well as licensing transactions, mergers and acquisitions. Most recently, he served as Chief Operating Officer of OvaScience, a life science company focused on the discovery and development of novel infertility treatment therapies.
In previous years, he held leadership roles with Cytyc Corporation (now Hologic, Inc.), Intact Medical Corporation (acquired by Medtronic plc) and Incept BioSystems, Inc. (acquired by ORIGIO a / s). He began his career with Abbot Laboratories, where he held increasingly senior positions over the course of 18 years (eg Corporate Vice President of Pediatric Products and President of Abbott Canada). Mr. Bleck holds a Bachelor's Degree (BS) in Pharmacy and a Masters Degree (MBA) from the University of Connecticut.
Imagin develops powerful new imaging solutions for cancer detection and imaging. The company is convinced that its technology will revolutionize cancer therapy. In minimally invasive procedures, the surgeon is able to visually visualize, detect, and remove cancer cells. Imagin's first target market is bladder cancer. Imagin's advanced, ultra-sensitive imaging technology was developed at the Lawrence Livermore National Laboratory and is based on improved optical design and advanced light sensors.
Cost of high risk of relapse The high risk of recurrence also has financial consequences: According to a 2009 World Urology Journal report, bladder cancer causes the highest cost of care per patient among bladder cancers. Responsible for this are the high recurrence rate and the continuing invasive surveillance of the disease.
The diagnosis of bladder cancer is not a death sentence. With effective intervention , bladder cancer survival rates can be quite high. If diagnosed early, surgical procedures are used to remove cancerous tissue. In addition, the surgery can be successful with minimally invasive procedures, sometimes even on an outpatient basis in the clinic of a urologist. Within a few years of the launch of the i / Blue system, significant penetration of the system in each hospital across the country can be expected. And hospitals are not the only market goal. There are also thousands of urology clinics in the i / Blue market where minimally invasive surgical procedures are routinely practiced today.
In the US alone, Imagins i / Blue technology could be in demand tens of thousands. The market volume, not least in connection with the contrast agent used, goes into the hundreds of millions of dollars. These are orders of magnitude that could also be attractive to established medical technology companies. For this reason, Imagin's visualization technology is also an ideal candidate for acquiring intellectual property rights.
The global market for the i / Blue system is likely to be a multiple of the US market. In Europe today, 17,000 urologists provide a population of 730 million people. As in America , the need for more is expected to increase sharply in the coming years.
Another director experienced in the aquisition game.
FDA process underway.
Its just time now guys. Its only a matter of time. Patience will pay huge here.
We probably both have different sell #'s
I didnt sell in the 40's but somewhere in the 80's im cashing some in. I will hold the rest.
Been in this since 2016. Im in no rush, i will see it through.
Lets get this
Good for you dude. Buyout or not were gonna make serious money on this one.
Wow looking ready to explode. Last chance to make $$.
You are wrong, company is legit up.and down. Tech is legit up and down. Are they behind? Yes. Perfect buying time. Go get it. Make some $$
Something is going on in the background. Longs hang on. Swing traders your up.
Its GMP securitues buying up the shares. Thats an investment firm. Great sign.
Walk up before news pops? If it spikes at the end of the day frome here. Monday will be glorious. Lets see
For those of you following at home. This is called the "walk up" MM's have been toying with the weak hands all summer. Nothing but happy shareholders from here up.
Imagin Medical Reports Fiscal 2018 Third Quarter Results
VANCOUVER, B.C. and BOSTON, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTCQB:IMEXF) (Frankfurt:DPD2) (Stuttgart:DPD2) (“Imagin” or the “Company”) today reported financial results for the three months ended June 30, 2018. All amounts, unless specified otherwise, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, applicable to the preparation of interim financial statements, including IAS-34, Interim Financial Reporting.
Recent Developments
Completed an oversubscribed private placement for total gross proceeds of $3,942.360.
Uplisted to the OTCQB Venture Market.
Announced favorable results in the 10-subject investigator-sponsored research study being conducted at the University of Rochester Medical Center using the i/Blue Imaging System (the “URMC Research Study”).
Reported that Optel, Inc., Imagin’s opto-electronic design firm, successfully completed the Proof of Concept phase of product development, verifying the performance of the two critical optical modules of the i/Blue Imaging System – the light source module and the imaging module.
“We have made significant progress to-date in the development of the i/Blue Imaging System,” said Jim Hutchens, Imagin’s President and CEO. “Moving forward, the proceeds from the recent private placement financing provides us with the necessary resources to continue executing our plans to bring this potentially game-changing technology to doctors and their patients. To that end, we anticipate submitting a pre-submission package to the FDA by the end of the calendar third quarter, and we will also be working closely with Optel to complete the functional unit, the second phase of our product development.”
Summary Fiscal 2018 Third Quarter Financial Results
Total operating expenses for the third quarter of fiscal 2018 were $1,041,809, compared to $275,463 from the same quarter in 2017, and consisted primarily of general and administrative (“G&A”) and research and development (“R&D”) expenses. G&A expenses for the three months ended June 30, 2018 were $740,446, compared with $197,583 in the same quarter a year ago. The increase in G&A expenses was largely attributable to an increase in legal and marketing fees. R&D expenses for the quarter ended June 30, 2018 were $301,361, compared with $77,880 for the same quarter in 2017. The increase in R&D expenses was primarily related to the work performed by Optel, as well as fees related to the URMC Research Study.
Net other expense, consisting primarily of non-cash stock-based compensation, offset partially by interest income and foreign exchange gains, was $735,592 in the third quarter of fiscal 2018, compared with net other expense of $22,161, consisting primarily of non-cash stock-based compensation and foreign exchange losses, in the same quarter in 2017.
Net loss for the three months ended June 30, 2018 was $1,751,665, or $0.02 loss per common share, as compared to a net loss of $298,242, or $0.01 loss per common share, for the three months ended June 30, 2017.
Liquidity and Outstanding Share Capital
As of June 30, 2018, the Company had cash of $6,045,863.
As of August 14, 2018, Imagin had an unlimited number of authorized common shares with 128,187,238 common shares issued and outstanding.
The Company's financial statements and management's discussion and analysis are available on www.sedar.com.
Then go. Why ya gotta say goodbye? Don't sell your shares.... take care
The answer is none. One insider sold at the beginning of the year because he was let go from the board. Bill Galine.
If you look at the form 11 on the CSE website the options granted are still alive. Even the ones @ .15 issued years ago that could have been cashed in when the sp hit the .40's.
Bigger picture will prevaile.
IME is by far not the only stock being hit/minipulated
Buy in July!!
They are still going over there. Those exchanges are worse than being on the grey market when it comes to CSE stocks. They move at like 2% of what we do.
Buy in July!
Not true. September PP the price Rose to .42 by January ish.
The task at hand now is to get the remaining warrants cashed. The .10 will be easy, but the .38 warrants are a little different and still have 21 months to expirey.
The next thing we need to hear is that we are setting up shop in UC Davis for the next round of testing.
I am not sure if they can report on FDA progress or lack of, until it's completed.
The risk/reward in this stock is tremendous. These prices are still cheap as hell.
This company has put all long term shareholders through the ringer with their timelines. But they did just knock one out. Unfortunately I think they knocked it out last month and delayed telling us because of a social media mistake.
Nonetheless on to the next phase. Good luck.
I can live with that. Hopefully we are on track for the UC Davis and Rochester clinical studies. On to the next phase.
VANCOUVER, British Columbia and BOSTON, July 17, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE:IME) (OTCQB:IMEXF) (Frankfurt:DPD2) (Stuttgart:DPD2) (“Imagin” or the “Company”) announced today favorable results in the 10-subject investigator-sponsored research study being conducted at the University of Rochester Medical Center using the i/Blue Imaging System (the “URMC Research Study”), an important step in the development of a commercially-viable product.
In the URMC Research Study, fluorescence was successfully demonstrated in 15 minutes, confirming that the i/Blue Imaging System will potentially allow physicians to “see” bladder cancer significantly faster than the full hour or more required by currently available imaging technology.
“While a backorder on certain component parts needed to make system adjustments during the URMC Research Study caused some delay, we are obviously very pleased with the outcome,” said Jim Hutchens, Imagin’s President and CEO. “This is an exciting time. We believe that the i/Blue Imaging System holds great promise for improving physicians’ ability to detect cancer and visualize the surgical field where endoscopes are used. To that end, we look forward to updating our stakeholders as we progress.”
Information gathered from the URMC Research Study is being used to help optimize Imagin’s i/Blue technology to further the development of a commercially-viable device system in preparation for the Company’s planned clinical trials to support its application to the U.S. Food and Drug Administration (“FDA”) for approval to market the i/Blue Imaging System in the United States.
“Imagin is grateful to the University of Rochester Medical Center for initiating and conducting this investigator-sponsored human research study,” commented Pam Papineau, Imagin’s Director of Regulatory and Clinical Affairs. “Imagin was pleased to provide early prototype equipment to assist the investigators in testing the underlying hypothesis that the i/Blue Imaging System can potentially identify protoporphyrin IX (PpIX) fluorescence associated with bladder cancer lesions in the presence of the contrasting agent, hexaminolevulinate hydrochloride. This project was undertaken prior to the commencement of an FDA application, and provides important insights that will help guide the Company in an FDA-compliant process. Imagin anticipates initiating preliminary discussions with the FDA regarding the i/Blue Imaging System as soon as possible.”
Running parallel to the URMC Research Study, the i/Blue Imaging System design and development has moved forward, incorporating feedback from the study into the system’s opto-electronic functions and features. As previously reported, Optel, Inc., Imagin’s opto-electronic design firm, is working against three phases of development: Proof of Concept, Functional Unit and Verified Unit. Of the three phases, the Proof of Concept phase has now been completed, verifying the performance of the two critical optical modules of the i/Blue Imaging System – the light source module and the imaging module.
Jay Eastman, Ph.D., CEO of Optel, stated, “The lessons learned from the URMC Research Study has provided valuable technical data, clinical insight and physician feedback that is significantly influencing the design of the i/Blue System. All of this information continues to increase our confidence that the miniaturization, imaging quality and cost reduction goals for the i/Blue System important to surgeons performing bladder cancer procedures.”
About Imagin Medical
Thanks AMG!
Stay on as a mod please.
Go nuts. I don't have the time. It would be greatly appreciated. Thanks AMG!!
Nah...This is accumulation time. One who is long should not care about the day to day share price. It's all about the end game. Everyone has a different end #. I'll.get mine you do what you have to.